Dasatinib Accord

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
30-03-2023
Karakteristik produk Karakteristik produk (SPC)
30-03-2023

Bahan aktif:

dasatinib

Tersedia dari:

Accord Healthcare S.L.U.

Kode ATC:

L01EA02

INN (Nama Internasional):

dasatinib (anhydrous)

Kelompok Terapi:

Antineoplastic agents

Area terapi:

Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Indikasi Terapi:

Dasatinib Accord is indicated for the treatment of adult patients with:• Ph+ acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy.Dasatinib Accord is indicated for the treatment of paediatric patients with:• newly diagnosed Ph+ ALL in combination with chemotherapy.

Ringkasan produk:

Revision: 1

Status otorisasi:

Withdrawn

Tanggal Otorisasi:

2022-03-24

Selebaran informasi

                                49
B. PACKAGE LEAFLET
Medicinal product no longer authorised
50
PACKAGE LEAFLET: INFORMATION FOR THE USER
DASATINIB ACCORD 20 MG FILM-COATED TABLETS
DASATINIB ACCORD 50 MG FILM-COATED TABLETS
DASATINIB ACCORD 70 MG FILM-COATED TABLETS
DASATINIB ACCORD 80 MG FILM-COATED TABLETS
DASATINIB ACCORD 100 MG FILM-COATED TABLETS
DASATINIB ACCORD 140 MG FILM-COATED TABLETS
dasatinib
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Dasatinib Accord is and what it is used for
2.
What you need to know before you take Dasatinib Accord
3.
How to take Dasatinib Accord
4.
Possible side effects
5.
How to store Dasatinib Accord
6.
Contents of the pack and other information
1.
WHAT DASATINIB ACCORD IS AND WHAT IT IS USED FOR
Dasatinib Accord contains the active substance dasatinib. This
medicine is used to treat Philadelphia
chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). It is
used in adults who are not
benefiting from previous therapies, as well as being combined with
other cancer medicines in
adolescents and children from 1 year of age with newly diagnosed Ph+
ALL. In people with ALL,
white cells called lymphocytes multiply too quickly and live too long.
Dasatinib Accord inhibits the
growth of these leukaemic cells.
If you have any questions about how Dasatinib Accord works or why this
medicine has been
prescribed for you, ask your doctor.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE DASATINIB ACCORD
_ _
DO NOT TAKE DASATINIB ACCORD
-
if you are
ALLERGIC
to dasatinib or any of the other ingredients of 
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Dasatinib Accord 20 mg film-coated tablets
Dasatinib Accord 50 mg film-coated tablets
Dasatinib Accord 70 mg film-coated tablets
Dasatinib Accord 80 mg film-coated tablets
Dasatinib Accord 100 mg film-coated tablets
Dasatinib Accord 140 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Dasatinib Accord 20 mg film-coated tablets
Each film-coated tablet contains 20 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 27 mg of lactose (as monohydrate).
Dasatinib Accord 50 mg film-coated tablets
Each film-coated tablet contains 50 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 67.5 mg of lactose (as monohydrate).
Dasatinib Accord 70 mg film-coated tablets
Each film-coated tablet contains 70 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 94.5 mg of lactose (as monohydrate).
Dasatinib Accord 80 mg film-coated tablets
Each film-coated tablet contains 80 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 108 mg of lactose (as monohydrate).
Dasatinib Accord 100 mg film-coated tablets
Each film-coated tablet contains 100 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 135.0 mg of lactose (as monohydrate).
Dasatinib Accord 140 mg film-coated tablets
Each film-coated tablet contains 140 mg dasatinib.
_Excipient with known effect _
Each film-coated tablet contains 189 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Dasatinib Accord 20 mg film-coated tablets
Medicinal product no longer authorised
3
White to off-white, round, 5.6 mm of diameter, coated tablets debossed
on one side with "DAS" and
"20" on the other side.
Dasatinib Accord 50 mg film-coated tablets
White to off-white, oval, 5.7 x 10.6 mm, coated tablets debossed on
one side with "DAS" and "50" on
the other
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 30-03-2023
Karakteristik produk Karakteristik produk Bulgar 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Bulgar 30-03-2023
Selebaran informasi Selebaran informasi Spanyol 30-03-2023
Karakteristik produk Karakteristik produk Spanyol 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Spanyol 30-03-2023
Selebaran informasi Selebaran informasi Cheska 30-03-2023
Karakteristik produk Karakteristik produk Cheska 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Cheska 30-03-2023
Selebaran informasi Selebaran informasi Dansk 30-03-2023
Karakteristik produk Karakteristik produk Dansk 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Dansk 30-03-2023
Selebaran informasi Selebaran informasi Jerman 30-03-2023
Karakteristik produk Karakteristik produk Jerman 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Jerman 30-03-2023
Selebaran informasi Selebaran informasi Esti 30-03-2023
Karakteristik produk Karakteristik produk Esti 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Esti 30-03-2023
Selebaran informasi Selebaran informasi Yunani 30-03-2023
Karakteristik produk Karakteristik produk Yunani 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Yunani 30-03-2023
Selebaran informasi Selebaran informasi Prancis 30-03-2023
Karakteristik produk Karakteristik produk Prancis 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Prancis 30-03-2023
Selebaran informasi Selebaran informasi Italia 30-03-2023
Karakteristik produk Karakteristik produk Italia 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Italia 30-03-2023
Selebaran informasi Selebaran informasi Latvi 30-03-2023
Karakteristik produk Karakteristik produk Latvi 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Latvi 30-03-2023
Selebaran informasi Selebaran informasi Lituavi 30-03-2023
Karakteristik produk Karakteristik produk Lituavi 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Lituavi 30-03-2023
Selebaran informasi Selebaran informasi Hungaria 30-03-2023
Karakteristik produk Karakteristik produk Hungaria 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Hungaria 30-03-2023
Selebaran informasi Selebaran informasi Malta 30-03-2023
Karakteristik produk Karakteristik produk Malta 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Malta 30-03-2023
Selebaran informasi Selebaran informasi Belanda 30-03-2023
Karakteristik produk Karakteristik produk Belanda 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Belanda 30-03-2023
Selebaran informasi Selebaran informasi Polski 30-03-2023
Karakteristik produk Karakteristik produk Polski 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Polski 30-03-2023
Selebaran informasi Selebaran informasi Portugis 30-03-2023
Karakteristik produk Karakteristik produk Portugis 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Portugis 30-03-2023
Selebaran informasi Selebaran informasi Rumania 30-03-2023
Karakteristik produk Karakteristik produk Rumania 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Rumania 30-03-2023
Selebaran informasi Selebaran informasi Slovak 30-03-2023
Karakteristik produk Karakteristik produk Slovak 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Slovak 30-03-2023
Selebaran informasi Selebaran informasi Sloven 30-03-2023
Karakteristik produk Karakteristik produk Sloven 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Sloven 30-03-2023
Selebaran informasi Selebaran informasi Suomi 30-03-2023
Karakteristik produk Karakteristik produk Suomi 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Suomi 30-03-2023
Selebaran informasi Selebaran informasi Swedia 30-03-2023
Karakteristik produk Karakteristik produk Swedia 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Swedia 30-03-2023
Selebaran informasi Selebaran informasi Norwegia 30-03-2023
Karakteristik produk Karakteristik produk Norwegia 30-03-2023
Selebaran informasi Selebaran informasi Islandia 30-03-2023
Karakteristik produk Karakteristik produk Islandia 30-03-2023
Selebaran informasi Selebaran informasi Kroasia 30-03-2023
Karakteristik produk Karakteristik produk Kroasia 30-03-2023
Laporan Penilaian publik Laporan Penilaian publik Kroasia 30-03-2023

Peringatan pencarian terkait dengan produk ini